Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 42

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 42
---
 uncertainties include, but are not limited to, those factors described in “ Risk Factors,” those discussed and identified in public filings made with the SEC by Denali and the following:

| • |     | our ability to complete the Business Combination with Semnur or, if we do not consummate such Business Combination, any other initial business combination; |

| • |     | satisfaction or waiver (if applicable) of the conditions to the consummation of the Business Combination, including the approval of the Merger Agreement by the shareholders of Denali; |

| • |     | the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; |

| • |     | the projected financial information, including Semnur’s forecasts (included in the section titled “Proposal 1 — The Business Combination Proposal — Certain Semnur Projected Financial Information”), anticipated growth rate, and market opportunity of New Semnur; |

| • |     | the ability to obtain and/or maintain the listing of New Semnur Common Stock on Nasdaq (or such other exchange as agreed by the parties, including the New York Stock Exchange (“NYSE”)) following the Business Combination; |

| • |     | New Semnur’s public securities’ potential liquidity and trading; |

| • |     | New Semnur’s ability to raise financing in the future; |

| • |     | New Semnur’s expected use of proceeds from future issuances of equity or convertible debt securities; |

5

| • |     | New Semnur’s future financial performance, including its revenue, costs of revenue and operating expenses; |

| • |     | the ability to realize the anticipated benefits of the Business Combination; |

| • |     | costs related to the Business Combination; |

| • |     | the outcome of any legal proceedings that may be instituted against Denali or Semnur related to the Business Combination; |

| • |     | the attraction and retention of qualified directors, officers, employees and key personnel of Denali and Semnur prior to the Business Combination, and New Semnur following the Business Combination; |

| • |     | the ability of Semnur to compete effectively in a highly competitive market; |

| • |     | the competition from larger pharmaceutical companies that have greater resources, technology, relationships and/or expertise; |

| • |     | the ability to protect and enhance Semnur’s corporate reputation and brand; |

| • |     |